On November 4, 2024, Rosty Raykov, a Director at Fennec Pharmaceuticals Inc (FENC, Financial), executed a sale of 2,431 shares of the company. The transaction was filed on the same day through an SEC Filing. Following this transaction, the insider now owns 66,432 shares of Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a biopharmaceutical company focused on the development of PEDMARK, a formulation of sodium thiosulfate intended to reduce the incidence of hearing loss in pediatric cancer patients receiving platinum-based chemotherapy.
Over the past year, Rosty Raykov has sold a total of 174,884 shares and has not purchased any shares. This recent sale is part of a broader trend observed within the company, where there have been 23 insider sells and no insider buys over the past year.
Shares of Fennec Pharmaceuticals Inc were priced at $4.31 on the day of the sale. The company has a market cap of approximately $127.91 million. The price-earnings ratio of the stock stands at 116.25, which is above the industry median of 26.485.
For more detailed valuation metrics such as price-sales ratio, price-book ratio, and price-to-free cash flow, interested parties are encouraged to visit the respective links.
This insider sale might be of interest to investors tracking insider behaviors and company stock performance, particularly in the biopharmaceutical sector.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
